HCPLive

Cervical Spine Instabilities Frequently Develop in Patients with Rheumatoid Arthritis

 
MONDAY, Jan. 7 (HealthDay News) -- Nearly half of all patients with rheumatoid arthritis (RA) initially without any cervical spine instabilities will develop some type of instability within about five years, according to research published in the Dec. 15 issue of Spine.

Takashi Yurube, M.D., of the Kobe University Graduate School of Medicine in Japan, and colleagues conducted a prospective, minimum five-year follow-up study of 140 patients with RA and no cervical involvement to assess the incidence and aggravation of cervical spine instabilities.

During approximately six years of follow-up, the researchers found that 43.6 percent of RA patients developed some type of cervical instability. Of these, 32.1 percent developed atlantoaxial subluxation (AAS), 11.4 percent developed vertical subluxation (VS), and 16.4 percent developed subaxial subluxation (SAS). Severe cervical instability was noted in 12.9 percent of all patients (AAS in 3.6 percent, VS in 6.4 percent, and SAS in 5.0 percent), and 4.3 percent developed canal stenosis, defined as space available for the spinal cord of 13 mm or less. Corticosteroid administration, mutilating changes at baseline, and development of non-mutilating into mutilating changes correlated significantly with severe instabilities.

"In conclusion, our prospective follow-up study describes the detailed incidence and predictors of cervical spine instabilities, providing useful information for clinical follow-up in patients with RA," the authors write. "Established mutilating changes and progressive development of non-mutilating into mutilating changes indicate poor prognosis of the cervical spine in patients with RA. Intensive corticosteroid treatment also correlates with the aggravation of cervical spine instabilities in RA; however, its clinical significance needs to be carefully examined."
 

Full Text

Copyright © 2013 HealthDay. All rights reserved.
 

Most Popular

Recommended Reading

A recent study looked into the neural functions affected by ibuprofen and found some connections that may soon lead to a much greater understanding of the greatest pain mitigator of them all: the brain.
The US Food and Drug Administration (FDA) on Thursday approved Orkambi (lumacaftor/ivacaftor/Vertex) to treat cystic fibrosis patients age 12 and older with two copies of the F508del mutation in the CFTR gene.
A novel virus from Peru and the Republic of Congo called enterovirus C105 is now suspected in last year's wave of mysterious cases of sudden childhood paralysis.
As more research is done the more it appears brown fat will play a key role in the future treatment of diabetes.
$vAR$